Johnson & Johnson (0R34.IL)
| Previous close | 149.60 |
| Open | 0.00 |
| Bid | 144.60 x N/A |
| Ask | 152.60 x N/A |
| Day's range | 148.39 - 148.39 |
| 52-week range | 143.14 - 175.85 |
| Volume | |
| Avg. volume | 161,726 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Johnson & Johnson Insiders Sold US$6.8m Of Shares Suggesting Hesitancy
Many Johnson & Johnson ( NYSE:JNJ ) insiders ditched their stock over the past year, which may be of interest to the...
- Yahoo Finance
J&J CFO: We've 'beefed up' cardiovascular medical devices in hopes of reviving our medtech business
J&J is doubling down on medtech, a typically sleepy sector that has been risky, as it looks to grow after spinning of consumer health segment Kenvue.
- Yahoo Finance Video
Johnson & Johnson reports mixed Q1 earnings, narrows guidance
Johnson & Johnson (JNJ) reported a mixed bag of first quarter results, missing revenue estimates but beating on the bottom line. The company's revenue came in at $21.38 billion, slightly below the street's expectation of $21.39 billion. However, Johnson & Johnson managed to surpass analyst estimates on adjusted earnings per share (EPS), posting $2.71 versus the expected $2.65. Yahoo Finance's Anjalee Khemlani breaks down the details of the earnings report, highlighting the company's pharmaceutical sector developments. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith
